ID   IRAK1_BOVIN             Reviewed;         718 AA.
AC   Q2LGB3;
DT   09-JAN-2007, integrated into UniProtKB/Swiss-Prot.
DT   21-MAR-2006, sequence version 2.
DT   07-APR-2021, entry version 114.
DE   RecName: Full=Interleukin-1 receptor-associated kinase 1;
DE            Short=IRAK-1;
DE            EC=2.7.11.1;
GN   Name=IRAK1;
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Laurasiatheria; Artiodactyla; Ruminantia; Pecora; Bovidae;
OC   Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Mammary gland;
RX   PubMed=16621030; DOI=10.1016/j.vetimm.2006.03.003;
RA   Connor E.E., Cates E.A., Williams J.L., Bannerman D.D.;
RT   "Cloning and radiation hybrid mapping of bovine toll-like receptor-4 (TLR-
RT   4) signaling molecules.";
RL   Vet. Immunol. Immunopathol. 112:302-308(2006).
CC   -!- FUNCTION: Serine/threonine-protein kinase that plays a critical role in
CC       initiating innate immune response against foreign pathogens. Involved
CC       in Toll-like receptor (TLR) and IL-1R signaling pathways. Is rapidly
CC       recruited by MYD88 to the receptor-signaling complex upon TLR
CC       activation. Association with MYD88 leads to IRAK1 phosphorylation by
CC       IRAK4 and subsequent autophosphorylation and kinase activation.
CC       Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and
CC       PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then,
CC       the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated
CC       IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the
CC       NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA
CC       and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and
CC       activation. Alternatively, phosphorylates TIRAP to promote its
CC       ubiquitination and subsequent degradation. Phosphorylates the
CC       interferon regulatory factor 7 (IRF7) to induce its activation and
CC       translocation to the nucleus, resulting in transcriptional activation
CC       of type I IFN genes, which drive the cell in an antiviral state. When
CC       sumoylated, translocates to the nucleus and phosphorylates STAT3 (By
CC       similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Homodimer (By similarity). Forms a complex with TRAF6, PELI1,
CC       IRAK4 and MYD88 (By similarity). Direct binding of SMAD6 to PELI1
CC       prevents complex formation and hence negatively regulates IL1R-TLR
CC       signaling and eventually NF-kappa-B-mediated gene expression (By
CC       similarity). The TRAF6-PELI1-IRAK1-IRAK4-MYD88 complex recruits
CC       MAP3K7/TAK1, TAB1 and TAB2 to mediate NF-kappa-B activation (By
CC       similarity). Interaction with MYD88 recruits IRAK1 to the stimulated
CC       receptor complex (By similarity). Interacts with TOLLIP; this
CC       interaction occurs in the cytosol prior to receptor activation (By
CC       similarity). Interacts with IL1RL1 (By similarity). Interacts (when
CC       polyubiquitinated) with IKBKG/NEMO (By similarity). Interacts with
CC       RSAD2/viperin (By similarity). Interacts with IRAK1BP1 (By similarity).
CC       Interacts with PELI2 (By similarity). Interacts with ZC3H12A; this
CC       interaction increases the interaction between ZC3H12A and IKBKB/IKKB
CC       (By similarity). Interacts with IRAK4 (By similarity). Interacts with
CC       PELI3 (By similarity). Interacts with PELI1 and TRAF6 (By similarity).
CC       Interacts with INAVA; the interaction takes place upon PRR stimulation
CC       (By similarity). Interacts (via C-terminus) with NFATC4 (via N-
CC       terminus) (By similarity). {ECO:0000250|UniProtKB:P51617,
CC       ECO:0000250|UniProtKB:Q62406}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus {ECO:0000250}.
CC       Lipid droplet {ECO:0000250}. Note=Translocates to the nucleus when
CC       sumoylated. RSAD2/viperin recruits it to the lipid droplet (By
CC       similarity). {ECO:0000250}.
CC   -!- DOMAIN: The ProST region is composed of many proline and serine
CC       residues (more than 20 of each) and some threonines. This region is the
CC       site of IRAK-1 hyperphosphorylation (By similarity). {ECO:0000250}.
CC   -!- PTM: Following recruitment on the activated receptor complex,
CC       phosphorylated on Thr-209, probably by IRAK4, resulting in a
CC       conformational change of the kinase domain, allowing further
CC       phosphorylations to take place. Thr-387 phosphorylation in the
CC       activation loop is required to achieve full enzymatic activity (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Polyubiquitinated by TRAF6 after cell stimulation with IL-1-beta
CC       by PELI1, PELI2 and PELI3. Polyubiquitination occurs with polyubiquitin
CC       chains linked through 'Lys-63'. Ubiquitination promotes interaction
CC       with NEMO/IKBKG. Also sumoylated; leading to nuclear translocation (By
CC       similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. Pelle subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; DQ319075; ABC47878.2; -; mRNA.
DR   RefSeq; NP_001035645.1; NM_001040555.1.
DR   SMR; Q2LGB3; -.
DR   STRING; 9913.ENSBTAP00000021407; -.
DR   PaxDb; Q2LGB3; -.
DR   PRIDE; Q2LGB3; -.
DR   Ensembl; ENSBTAT00000021407; ENSBTAP00000021407; ENSBTAG00000016085.
DR   GeneID; 533953; -.
DR   KEGG; bta:533953; -.
DR   CTD; 3654; -.
DR   VGNC; VGNC:30264; IRAK1.
DR   eggNOG; KOG1187; Eukaryota.
DR   GeneTree; ENSGT00940000160502; -.
DR   HOGENOM; CLU_000288_173_1_1; -.
DR   InParanoid; Q2LGB3; -.
DR   OrthoDB; 684563at2759; -.
DR   Proteomes; UP000009136; Chromosome X.
DR   ExpressionAtlas; Q2LGB3; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005811; C:lipid droplet; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0032991; C:protein-containing complex; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046982; F:protein heterodimerization activity; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IEA:Ensembl.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0106311; F:protein threonine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0007250; P:activation of NF-kappaB-inducing kinase activity; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IBA:GO_Central.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0070498; P:interleukin-1-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IEA:Ensembl.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IBA:GO_Central.
DR   GO; GO:1904996; P:positive regulation of leukocyte adhesion to vascular endothelial cell; IEA:Ensembl.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IBA:GO_Central.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IBA:GO_Central.
DR   GO; GO:1901224; P:positive regulation of NIK/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0001959; P:regulation of cytokine-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0034134; P:toll-like receptor 2 signaling pathway; IBA:GO_Central.
DR   GO; GO:0034142; P:toll-like receptor 4 signaling pathway; IBA:GO_Central.
DR   GO; GO:0060337; P:type I interferon signaling pathway; IEA:Ensembl.
DR   CDD; cd08794; Death_IRAK1; 1.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR000488; Death_domain.
DR   InterPro; IPR035533; Death_IRAK1.
DR   InterPro; IPR035536; IRAK1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24419:SF1; PTHR24419:SF1; 1.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   2: Evidence at transcript level;
KW   ATP-binding; Cytoplasm; Immunity; Innate immunity; Isopeptide bond; Kinase;
KW   Lipid droplet; Magnesium; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Ubl conjugation.
FT   CHAIN           1..718
FT                   /note="Interleukin-1 receptor-associated kinase 1"
FT                   /id="PRO_0000269708"
FT   DOMAIN          27..106
FT                   /note="Death"
FT   DOMAIN          212..521
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         218..226
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         342..345
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          110..211
FT                   /note="ProST region"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        104..194
FT                   /note="Pro-rich"
FT   COMPBIAS        693..696
FT                   /note="Poly-Ser"
FT   ACT_SITE        340
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         239
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         358
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         66
FT                   /note="Phosphothreonine; by PKC/PRKCI"
FT                   /evidence="ECO:0000250|UniProtKB:P51617"
FT   MOD_RES         209
FT                   /note="Phosphothreonine; by IRAK4"
FT                   /evidence="ECO:0000250|UniProtKB:P51617"
FT   MOD_RES         375
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P51617"
FT   MOD_RES         387
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P51617"
FT   MOD_RES         556
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P51617"
FT   CROSSLNK        134
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P51617"
FT   CROSSLNK        180
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P51617"
SQ   SEQUENCE   718 AA;  77397 MW;  3B364180697DB1F0 CRC64;
     MAGGPGPGDP AVPGAQHFLY EVPPWVMCRF YKVMDALEPA DWCQFAALIV RDQTELRLCE
     RSGQRTASVL WPWINRNARV ADLVRILTHL QLLRARDIIT AWHPPAPLLP PSTTSLTPSS
     ISAPSEAAVP GHRKLPSLAS TFLSPAFPGS QTHSDPELCP GPSPAAHQPP LPSPAPSSTK
     PSPESPMSLL PGAPSSSFCW PLHEICQGTH DFSEELKIGE GGFGCVYRAV MRNTVYAVKR
     LKEEADLEWT TVKQSFQTEV QQLSRFRHPN IVDFAGYCAQ SGFYCLVYGF LPNGSLEDRL
     HVQTQAWPPL SWPQRLDILL GTARAIQFLH QDSPSLIHGD VKSSNVLLDE RLMPKLGDFG
     LARLSRFTGA NPGQSSSVAR TRTVRGTLAY LPEEYVKTGR LAVDTDTFSF GVVLLETLAG
     QRAVRMHGAQ PKYLKDLVEE EAEEAGVTLK GTQTAVQGGP AADTWAALVA AQIYKKHLDP
     RPGPCPPQLG LALGQLACCC LHRRAKRRPP MTQVYQTLEE LQVVVAGPCL ELEAASRSPP
     SPQENSYVST SGSALSRASP WQPLAAPLGA QAQATDWPQK GANQPVESDE SVSDLSAALH
     SWHLSPSCPA GPGAPSWVPA PFGQAACTQG GAARESSCGS GPGLQPTAVE GPLLGSSMSS
     RPPQIVINPA RRKMLQKLAL YEDGVLDSLQ LLSSSSLPDS GQDLQDRQGP EERDEFRS
//
